Skip to main content
. 2024 Dec 1;13(12):1150. doi: 10.3390/antibiotics13121150

Table 1.

Patient variables.

Parameter (n = 69 Patients) Value
Gender (male) (Nr., %) 31 (44.9%)
Age (mean ± SD, median (IQR)) 60.51 ± 16.7, 62 (49.5–75)
Septic shock (Nr., %) 27 (39.1%)
WBC (mean ± SD, median (IQR)) 16,390 ± 4680, 15.4 (13,411–18,560)
CRP (mean ± SD, median (IQR)) 152.96 ± 107.04, 113 (82.5–214)
Procalcitonin (mean ± SD, median (IQR)) 5.41 ± 8.49, 2.68 (0.8–5.4)
ASA Grading (Nr., %)
I 2 (2.9%)
II 37 (53.6%)
III 13 (18.8%)
IV 14 (20.3%)
V 3 (4.3%)
Comorbidities (Nr., %) 29 (42%)
Cardiovascular diseases (Nr., %) 29 (42%)
Diabetes mellitus type II (Nr., %) 3 (4.3%)
Modified Hinchey classification (Nr., %)
IIA 17 (24.6%)
IIB 30 (43.5%)
III 15 (21.7%)
IV 7 (10.1%)
Source control (Nr., %)
Laparoscopic drainage 30 (43.5%)
Laparoscopic resection + anastomosis 12 (17.4%)
Laparoscopic Hartmann 6 (8.7%)
Open resection + anastomosis 3 (4.3%)
Open Hartmann 18 (26.1%)
Identified pathogens (Nr., %) 48 (69.6%)
ICU admission (mean ± SD, median (IQR)) 1.72 ± 1.4, 1 (1–2)
ICU admission > 1 day (Nr., %) 27 (39.1%)
LOS (mean ± SD, median (IQR)) 7.87 ± 2.97, 8 (6–10)
LOS < 7 days 25 (36.2%)
LOS 7–10 days 31 (44.9%)
LOS > 10 days 13 (18.8%)
Empiric antibiotherapy–adequate (Nr., %) 36 (75%)
Mortality (Nr., %) 4 (5.8%)